Research programme: heat shock transcription factor stimulants - Chaperone Pharma

Drug Profile

Research programme: heat shock transcription factor stimulants - Chaperone Pharma

Alternative Names: NYK 1112; NYK 1341; NYK-1005; NYK-1007

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nyken
  • Developer Chaperone Pharma
  • Class
  • Mechanism of Action Heat shock transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute kidney injury; Delayed graft function
  • Research Heart failure
  • No development reported Atrial fibrillation

Most Recent Events

  • 28 May 2018 No recent reports of development identified for research development in Atrial-fibrillation in Netherlands (Infusion)
  • 19 May 2016 Early research development is ongoing for Atrial fibrillation in Netherlands (Nyken pipeline, May 2016)
  • 19 May 2016 NYK 1341 is available for licensing as of May 2016. http://www.nyken.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top